Ten Research Questions for Improving COPD Care in the Next Decade

References

• Boucher RC. Muco-obstructive lung diseases. N Engl J Med. 2019;380(20):1941–1953. doi:10.1056/NEJMra1813799.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Burney PG, Silverman EK. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1(1):15076. doi:10.1038/nrdp.2015.76.
   PubMed Web of Science ®Google Scholar
• Diab N, Gershon AS, Sin DD. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–1139. doi:10.1164/rccm.201804-0621CI.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable Traits Down Under International Workshop report. Eur Respir J. 2019;53(5):1802058. doi:10.1183/13993003.02058-2018.
   PubMed Web of Science ®Google Scholar
• Singh D, Barnes PJ, Stockley R, et al. Pharmacological treatment of COPD: the devil is always in the detail. Eur Respir J. 2018;51(4):1800263. doi:10.1183/13993003.00263-2018.
   PubMed Web of Science ®Google Scholar
• Wedzicha J-C, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Bhatt SP, Anzueto A, et al. Clinical epidemiology of COPD: insights from 10 years of the COPD gene study. Chest. 2019;156(2):228. doi:10.1016/j.chest.2019.04.135.
   PubMed Web of Science ®Google Scholar
• Echazarreta AL, Arias SJ, Del Olmo R, et al. Prevalence of COPD in 6 urban clusters in Argentina: the EPOC.AR study. Arch Bronconeumol. 2018;54(5):260–269. doi:10.1016/j.arbres.2017.09.018.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863–868. doi:10.1136/thx.2009.115725.
   PubMed Web of Science ®Google Scholar
• Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-6.
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ballestros K, Echko M, et al. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states. JAMA. 2018;319(14):1444–1472. doi:10.1001/jama.2018.0158.
   PubMed Web of Science ®Google Scholar
• Alfageme I, de Lucas P, Ancochea J, et al. 10 Years after EPISCAN: a new study on the prevalence of COPD in Spain—a summary of the EPISCAN II protocol. Arch Bronconeumol. 2019;55(1):38–47. doi:10.1016/j.arbres.2018.05.011.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lancet Respir Med. 2014;2(1):54–62. doi:10.1016/S2213-2600(13)70232-7.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X.
   PubMed Web of Science ®Google Scholar
• Chaffee BW, Couch ET, Gansky SA. Trends in characteristics and multi-product use among adolescents who use electronic cigarettes, United States 2011-2015. PLoS One. 2017;12(5):e0177073. doi:10.1371/journal.pone.0177073.
   PubMed Web of Science ®Google Scholar
• Bals R, Boyd J, Esposito S, et al. Electronic cigarettes: a task force report from the European Respiratory Society. Eur Respir J. 2019;53(2):1801151. doi:10.1183/13993003.01151-2018.
   PubMed Web of Science ®Google Scholar
• Scott A, Lugg ST, Aldridge K, et al. Pro-inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages. Thorax. 2018;73(12):1161–1169. doi:10.1136/thoraxjnl-2018-211663.
   PubMed Web of Science ®Google Scholar
• Reinikovaite V, Rodriguez IE, Karoor V, et al. The effects of electronic cigarette vapour on the lung: direct comparison to tobacco smoke. Eur Respir J. 2018;51(4):1701661. doi:10.1183/13993003.01661-2017.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. E-Cigarette Products: Safety Communication - Due to the Incidents of Severe Respiratory Disease Associated with Use of an E-Cigarette Product. Available at https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/e-cigarette-products-safety-communication-due-incidents-severe-respiratory-disease-associated-use-e Posted: 30/08/2019.
   Google Scholar
• Garudadri S, Woodruff PG. Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Annals ATS. 2018;15(Supplement_4):S234–s238. doi:10.1513/AnnalsATS.201808-533MG.
   Google Scholar
• Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019 Jul;74(7):1249-1256. doi:10.1111/all.13760.
   PubMed Web of Science ®Google Scholar
• Petersen H, Vazquez Guillamet R, Meek P, et al. Early endotyping: a chance for intervention in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2018;59(1):13–17. doi:10.1165/rcmb.2018-0002PS.
   PubMed Web of Science ®Google Scholar
• Borras-Santos A, Garcia-Aymerich J, Soler-Cataluna JJ, et al. Determinants of the appearance and progression of early-onset chronic obstructive pulmonary disease in young adults. A case-control study with follow-up. Arch Bronconeumol. 2019;55(6):312–318. doi:10.1016/j.arbres.2018.09.007.
   PubMed Web of Science ®Google Scholar
• Perez Rial S, Peces-Barba G. Do experimental COPD models make sense? Arch Bronconeumol. 2019;55(2):65–66. doi:10.1016/j.arbres.2018.06.021.
   PubMed Web of Science ®Google Scholar
• Li CX, Wheelock CE, Skold CM, et al. Integration of multi-omics datasets enables molecular classification of COPD. Eur Respir J. 2018;51(5):1701930. doi:10.1183/13993003.01930-2017.
   PubMed Web of Science ®Google Scholar
• Gea J, Pascual S, Castro-Acosta A, et al. The BIOMEPOC project: personalized biomarkers and clinical profiles in chronic obstructive pulmonary disease. Arch Bronconeumol. 2019;55(2):93–99. doi:10.1016/j.arbres.2018.07.026.
   PubMed Web of Science ®Google Scholar
• Verde Z, Santiago C, Chicharro LM, et al. Association of HTR2A-1438G/A genetic polymorphism with smoking and chronic obstructive pulmonary disease. Arch Bronconeumol. 2019;55(3):128–133. doi:10.1016/j.arbres.2018.07.021.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Gerhardsson de Verdier M, Agusti A, et al. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019 Feb 1;5(1).pii: 00036-2018. doi:10.1183/23120541.:.
   PubMedGoogle Scholar
• Fernandez-Villar A, Soriano JB, Lopez-Campos JL. Overdiagnosis of COPD: precise definitions and proposals for improvement. Br J Gen Pract. 2017;67(657):183–184. doi:10.3399/bjgp17X690389.
   PubMed Web of Science ®Google Scholar
• Riesco Miranda JA, Marca-Frances G, Jimenez-Ruiz CA. Perception and awareness of chronic obstructive pulmonary disease, chronic bronchitis and pulmonary emphysema in the Spanish urban population. Arch Bronconeumol. 2018;54(6):352–353. doi:10.1016/j.arbres.2017.12.008.
   PubMed Web of Science ®Google Scholar
• Abad-Arranz M, Moran-Rodriguez A, Mascaros Balaguer E, et al. Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit. Int J Chron Obstruct Pulmon Dis. 2019;14:1187–1194. doi:10.2147/copd.S199322.
   PubMed Web of Science ®Google Scholar
• Mohigefer J, Calero-Acuna C, Marquez-Martin E, et al. Understanding of COPD among final-year medical students. COPD. 2017;13:131–139. doi:10.2147/COPD.S138539.
   Google Scholar
• Spyratos D, Haidich AB, Chloros D, et al. Comparison of three screening questionnaires for chronic obstructive pulmonary disease in the primary care. Respiration. 2017;93(2):83–89. doi:10.1159/000453586.
   PubMed Web of Science ®Google Scholar
• Ruiz MP. Translation and validation of the multidimensional dyspnea-12 questionnaire. Arch Bronconeumol. 2019;55(1):64. doi:10.1016/j.arbres.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Schermer TR, Vatsolaki M, Behr R, et al. Point of care microspirometry to facilitate the COPD diagnostic process in primary care: a clustered randomised trial. NPJ Prim Care Respir Med. 2018;28(1):17. doi:10.1038/s41533-018-0083-9.
   PubMedGoogle Scholar
• Kjeldgaard P, Lykkegaard J, Spillemose H, et al. Multicenter study of the COPD-6 screening device: feasible for early detection of chronic obstructive pulmonary disease in primary care? COPD. 2017;12:2323–2331. doi:10.2147/COPD.S136244.
   Google Scholar
• Hidalgo Sierra V, Hernandez Mezquita MA, Palomo Cobos L, et al. Usefulness of the piko-6 portable device for early COPD detection in primary care. Arch Bronconeumol. 2018;54(9):460–466. doi:10.1016/j.arbres.2018.04.015.
   PubMed Web of Science ®Google Scholar
• Fernandez-Villar A, Represas-Represas C, Mouronte-Roibas C, et al. Reliability and usefulness of spirometry performed during admission for COPD exacerbation. PLoS One. 2018;13(3):e0194983. doi:10.1371/journal.pone.0194983.
   PubMed Web of Science ®Google Scholar
• Belgrave DCM, Granell R, Turner SW, et al. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. Lancet Respir Med. 2018;6(7):526–534. doi:10.1016/S2213-2600(18)30099-7.
   PubMed Web of Science ®Google Scholar
• Karimi R, Tornling G, Forsslund H, et al. Differences in regional air trapping in current smokers with normal spirometry. Eur Respir J. 2017;49(1):1600345. doi:10.1183/13993003.00345-2016.
   PubMed Web of Science ®Google Scholar
• Celli BR, Agusti A. COPD: time to improve its taxonomy? ERJ Open Res. 2018 Feb 16;4(1). pii: 00132-2017 doi:10.1183/23120541.:.
   PubMedGoogle Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–149. doi:10.1016/j.arbres.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Centanni S. Current approaches for phenotyping as a target for precision medicine in COPD management. COPD. 2018;15(2):108–117. doi:10.1080/15412555.2018.1443064.
   PubMedGoogle Scholar
• Golpe R, Suarez-Valor M, Castro-Anon O, et al. Risk stratification in chronic obstructive pulmonary disease. Can the Spanish guidelines be improved? Arch Bronconeumol. 2018;54(10):533–535. doi:10.1016/j.arbres.2018.01.035.
   PubMed Web of Science ®Google Scholar
• Pedone C, Giua R, Scichilone N, et al. GOLD Staging system is appropriate to predict mortality in older people with chronic obstructive pulmonary disease. Arch Bronconeumol. 2018 Mar 9. pii: S0300-2896(18)30037-1. doi:10.1016/j.arbres.2018.01.022.
   PubMed Web of Science ®Google Scholar
• Cabrera Lopez C, Casanova Macario C, Marin Trigo JM, et al. Prognostic validation using GesEPOC 2017 severity criteria. Arch Bronconeumol. 2019 Aug;55(8):409–413. doi:10.1016/j.arbres.2018.12.002.
   PubMed Web of Science ®Google Scholar
• Baloira Villar A, Palop Cervera M. Does the exacerbator phenotype in chronic obstructive pulmonary disease really exist? Arch Bronconeumol. 2018;54(3):119–120. doi:10.1016/j.arbres.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee CH, Lee MG, et al. Acute exacerbation according to GOLD 2017 categories in patients with chronic obstructive pulmonary disease. Arch Bronconeumol. 2019 Aug;55(8):414–420. doi:10.1016/j.arbres.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883.
   PubMed Web of Science ®Google Scholar
• Golpe R, Suarez-Valor M, Veiga-Teijeiro I, et al. Should lung function be included in the risk stratification of chronic obstructive pulmonary disease proposed by GesEPOC? Arch Bronconeumol. 2019 Aug;55(8):436–437. doi:10.1016/j.arbres.2018.12.007
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Soler-Cataluna JJ, Miravitlles M. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019 report: future challenges. Arch Bronconeumol. 2019. doi:10.1016/j.arbres.2019.06.001.
   Web of Science ®Google Scholar
• Lopez-Campos JL, Carrasco Hernandez L, Munoz X, et al. Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology. 2018;23(9):818. doi:10.1111/resp.13341.
   Web of Science ®Google Scholar
• Perez de Llano L, Cosio BG, Miravitlles M, et al. Accuracy of a new algorithm to identify asthma-COPD overlap (ACO) patients in a cohort of patients with chronic obstructive airway disease. Arch Bronconeumol. 2018;54(4):198–204. doi:10.1016/j.arbres.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Romero Palacios PJ. Clinical guidelines in asthma and chronic obstructive pulmonary disease: how useful are they in clinical practice? Arch Bronconeumol. 2018;54(3):117–118. doi:10.1016/j.arbres.2017.07.021.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221. doi:10.1164/rccm.201612-2525LE.
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Kang D, et al. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018;19(1):134. doi:10.1186/s12931-018-0840-x.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Ruiz Rodriguez O, Conde Baena P, et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51(1). doi:10.1183/13993003.01457-2017.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Santiago Diaz P, et al. Alveolar and bronchial nitric oxide in chronic obstructive pulmonary disease and asthma-COPD overlap. Arch Bronconeumol. 2018;54(8):414–419. doi:10.1016/j.arbres.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Perez de Llano L, Lopez-Campos JL, Cosio BG. The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study. Arch Bronconeumol. 2018;54(4):175–176. doi:10.1016/j.arbres.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis. J Allergy Clin Immunol. 2015;136(3):521–529. doi:10.1016/j.jaci.2015.06.018.
   PubMed Web of Science ®Google Scholar
• Figueira Goncalves JM, Garcia Bello MA, Martin Martinez MD, et al. Can the COPD-comorbidome be applied to all outpatients with chronic obstructive pulmonary disease? A single-center analysis. Arch Bronconeumol. 2019 May 18. pii: S0300-2896(19)30212-1. doi:10.1016/j.arbres.2019.03.016.
   Google Scholar
• Gazzotti MR, Roco CM, Pradella CO, et al. Frequency of osteoporosis and vertebral fractures in chronic obstructive pulmonary disease (COPD) patients. Arch Bronconeumol. 2019;55(5):252–257. doi:10.1016/j.arbres.2018.10.010.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Carrasco Hernandez L, Quintana Gallego E. The heart-lung dilemma in COPD: a tale of two cities. Arch Bronconeumol. 2019;55(4):185–186. doi:10.1016/j.arbres.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Laveneziana P, Albuquerque A, Aliverti A, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J. 2019;53(6):1801214. doi:10.1183/13993003.01214-2018.
   PubMed Web of Science ®Google Scholar
• Gea J, Martinez-Llorens J. Muscle dysfunction in chronic obstructive pulmonary disease: latest developments. Arch Bronconeumol. 2019;55(5):237–238. doi:10.1016/j.arbres.2018.07.016.
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Olveira Fuster C. Bronchiectasis in COPD and asthma. More than just a coincidence. Arch Bronconeumol. 2019;55(4):181–182. doi:10.1016/j.arbres.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Martin Guerra JM, Martin Asenjo M, Sanchez Munoz LA, et al. Hyponatremia in COPD: a little known complication. Arch Bronconeumol. 2018 Jan 12. pii: S0300-2896(17)30423-4. doi:10.1016/j.arbres.2017.11.006
   Web of Science ®Google Scholar
• Fanjul F, Soriano J. Do HIV-infected patients die of chronic obstructive pulmonary disease in western countries? Arch Bronconeumol. 2019;55(7):390–391. doi:10.1016/j.arbres.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Marin-Oto M, Marin JM. Obstructive sleep apnea syndrome and chronic obstructive pulmonary disease: overlap or syndrome. Arch Bronconeumol. 2018;54(10):499–500. doi:10.1016/j.arbres.2018.02.012.
   PubMed Web of Science ®Google Scholar
• Yeoh EK, Wong MCS, Wong ELY, et al. Benefits and limitations of implementing Chronic Care Model (CCM) in primary care programs: a systematic review. Int J Cardiol. 2018;258:279–288. doi:10.1016/j.ijcard.2017.11.057.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos E, Gimeno-Santos E, Hernandez C, et al. Recommendations on non-pharmacological treatment in chronic obstructive pulmonary disease from the Spanish COPD guidelines (GesEPOC 2017). Arch Bronconeumol. 2018;54(11):568–575. doi:10.1016/j.arbres.2018.06.001.
   PubMed Web of Science ®Google Scholar
• Carrion Valero F, Paulos Dos Santos S, Celli BR. Smoking in COPD patients: a new clinical phenotype? Arch Bronconeumol. 2018;54(5):249–250. doi:10.1016/j.arbres.2017.10.021.
   PubMed Web of Science ®Google Scholar
• Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380(7):629–637. doi:10.1056/NEJMoa1808779.
   PubMed Web of Science ®Google Scholar
• Halpern SD, Harhay MO, Saulsgiver K, et al. A pragmatic trial of E-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med. 2018;378(24):2302–2310. doi:10.1056/NEJMsa1715757.
   PubMed Web of Science ®Google Scholar
• Gomajee R, El-Khoury F, Goldberg M, et al. Association between electronic cigarette use and smoking reduction in France. JAMA Intern Med. 2019;179(9):1193. doi:10.1001/jamainternmed.2019.1483.
   Web of Science ®Google Scholar
• Charikiopoulou M, Nikolaidis PT, Knechtle B, et al. Subjective and objective outcomes in patients with COPD after pulmonary rehabilitation—the impact of comorbidities. Front Physiol. 2019;10:286. doi:10.3389/fphys.2019.00286.
   PubMed Web of Science ®Google Scholar
• Spruit MA, Pitta F, Garvey C, et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J. 2014;43(5):1326–1337. doi:10.1183/09031936.00145613.
   PubMed Web of Science ®Google Scholar
• Arbillaga-Etxarri A, Gimeno-Santos E, Barberan-Garcia A, et al. Long-term efficacy and effectiveness of a behavioural and community-based exercise intervention (Urban Training) to increase physical activity in patients with COPD: a randomised controlled trial. Eur Respir J. 2018;52(4):1800063. doi:10.1183/13993003.00063-2018.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Kaliaraju D, Jones SE, et al. Home versus outpatient pulmonary rehabilitation in COPD: a propensity-matched cohort study. Thorax. 2019;74(10):996. doi:10.1136/thoraxjnl-2018-212765.
   PubMed Web of Science ®Google Scholar
• Figueira Goncalves JM, Garcia Bello MA, Bethencourt Martin N, et al. Impact of 13-valent pneumococcal conjugate polysaccharide vaccination on severe exacerbations in patients with chronic obstructive pulmonary disease and established cardiovascular disease. Eur J Intern Med. 2019;63:e14–e16. doi:10.1016/j.ejim.2019.03.010.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Vandermeulen C, et al. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. 2019;37(23):3113–3122. doi:10.1016/j.vaccine.2019.04.041.
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Schembri S, Brightling C, et al. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: a phase 2 clinical trial. Vaccine. 2019;37(41):6102. doi:10.1016/j.vaccine.2019.07.100.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Van Damme P, Haazen W, et al. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. 2016;34(27):3156–3163. doi:10.1016/j.vaccine.2016.04.051.
   PubMed Web of Science ®Google Scholar
• Mayoralas-Alises S, Carratalá JM, Díaz-Lobato S. New perspectives in oxygen therapy titration: is automatic titration the future? Arch Bronconeumol. 2019;55(6):319–327. doi:10.1016/j.arbres.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Murphy PB, Hart N. Home non-invasive ventilation for COPD: how, who and when? Arch Bronconeumol. 2018;54(3):149–154. doi:10.1016/j.arbres.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Struik FM, Lacasse Y, Goldstein R. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013(6):CD002878. doi:10.1002/14651858.CD002878.pub2.
   Google Scholar
• Lopez-Campos JL, Caballero-Eraso C, Barrot-Cortés E. Home mechanical ventilation for stable COPD in GOLD 2017: what are we ventilating? Respirology. 2017;22(8):1497–1499. doi:10.1111/resp.13091.
   PubMed Web of Science ®Google Scholar
• Ergan B, Oczkowski S, Rochwerg B. European respiratory society guideline on long-term home non-invasive ventilation for management of chronic obstructive pulmonary disease. Eur Respir J. 2019 Aug 29. pii: 1901003. doi:10.1183/13993003.01003-2019.
   PubMedGoogle Scholar
• Nieto Cano S, Golpe Gómez R, Pérez de Llano LA. The need for palliative care in chronic respiratory patients with non-malignant disease. Arch Bronconeumol. 2018;54(1):57. doi:10.1016/j.arbres.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Ecenarro PS, Iguiñiz MI, Tejada SP, et al. Management of COPD in end-of-life care by Spanish pulmonologists. COPD. 2018;15(2):171–176. doi:10.1080/15412555.2018.1441274.
   PubMedGoogle Scholar
• Fernandez-Garcia S, Represas-Represas C, Ruano-Ravina A, et al. Social profile of patients admitted for COPD exacerbations. A gender analysis. Arch Bronconeumol. 2019 Apr 11. pii: S0300-2896(19)30120-6. doi:10.1016/j.arbres.2019.03.009.
   Google Scholar
• Fusi-Schmidhauser T, Riglietti A, Froggatt K, et al. Palliative care provision for patients with advanced chronic obstructive pulmonary disease: a systematic integrative literature review. COPD. 2018;15(6):600–611. doi:10.1080/15412555.2019.1566893.
   PubMedGoogle Scholar
• Rabinovich RA. Physical activity in COPD. Significance, prognosis, measurement and therapeutic interventions. Arch Bronconeumol. 2018;54(9):449–450. doi:10.1016/j.arbres.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Serra I, Gomez FP, et al. Physical activity and clinical and functional status in COPD. Chest. 2009;136(1):62–70. doi:10.1378/chest.08-2532.
   PubMed Web of Science ®Google Scholar
• Lear SA, Hu W, Rangarajan S, et al. The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet. 2017;390(10113):2643–2654. doi:10.1016/S0140-6736(17)31634-3.
   PubMed Web of Science ®Google Scholar
• Ramon MA, Gimeno-Santos E, Ferrer J, et al. Hospital admissions and exercise capacity decline in patients with COPD. Eur Respir J. 2014;43(4):1018–1027. doi:10.1183/09031936.00088313.
   PubMed Web of Science ®Google Scholar
• Barreiro E. Impact of physical activity and exercise on chronic obstructive pulmonary disease phenotypes: the relevance of muscle adaptation. Arch Bronconeumol. 2019 Jun 7. pii: S0300-2896(19)30252-2. doi:10.1016/j.arbres.2019.04.024.
   Web of Science ®Google Scholar
• Gimeno-Santos E. Pulmonary rehabilitation and long-term physical activity in the chronic obstructive pulmonary disease patient. Arch Bronconeumol. 2019 Jun 5. pii: S0300-2896(19)30258-3. doi:10.1016/j.arbres.2019.05.006.
   PubMedGoogle Scholar
• Ramon MA. Promoting physical activity after hospitalization for chronic obstructive pulmonary disease exacerbation. Arch Bronconeumol. 2019. doi:10.1016/j.arbres.2019.03.029.
   Web of Science ®Google Scholar
• Pleguezuelos E, Guirao L, Moreno E, et al. Safety of rehabilitation program for COPD patients. Arch Bronconeumol. 2018;54(2):111–112. doi:10.1016/j.arbres.2017.06.012.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Troosters T, Janssens W, et al. Multidisciplinary perspectives on the importance of physical activity in COPD. Arch Bronconeumol. 2019 Apr 11. pii: S0300-2896(19)30121-8. doi:10.1016/j.arbres.2019.03.010.
   Web of Science ®Google Scholar
• Soler-Cataluna JJ, Puente Maestu L, Roman-Rodriguez M, et al. Creation of the SAQ-COPD questionnaire to determine physical activity in COPD patients in clinical practice. Arch Bronconeumol. 2018;54(9):467–475. doi:10.1016/j.arbres.2018.01.016.
   PubMed Web of Science ®Google Scholar
• Cebollero P, Anton M, Hernandez M, et al. Walking program for COPD patients: clinical impact after two years of follow-up. Arch Bronconeumol. 2018;54(8):439–440. doi:10.1016/j.arbres.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Profita M, Bonanno A, Montalbano AM, et al. Beta(2) long-acting and anticholinergic drugs control TGF-beta1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012;1822(7):1079–1089. doi:10.1016/j.bbadis.2012.03.002.
   PubMed Web of Science ®Google Scholar
• Lee CM, Heo J, Han SS, et al. Inhaled corticosteroid-related tuberculosis in the real world among patients with asthma and COPD: a 10-year nationwide population-based study. J Allergy Clin Immunol Pract. 2019;7(4):1197–1206. e1193. doi:10.1016/j.jaip.2018.10.007.
   PubMed Web of Science ®Google Scholar
• Seijo LM, Peces-Barba G. Inhaled corticosteroids and lung cancer in COPD. Arch Bronconeumol. 2019 Aug;55(8):407–408. doi:10.1016/j.arbres.2019.01.031.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Castellano Minan F, Romero Palacios PJ. The future of triple therapy in chronic obstructive pulmonary disease. Arch Bronconeumol. 2018;54(2):63–64. doi:10.1016/j.arbres.2017.06.019.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Marquez-Martín E, Ortega-Ruiz F. Triple Therapy vs. Triple Therapy in COPD. Arch Bronconeumol. 2017 Aug;53(8):419–420. doi:10.1016/j.arbres.2017.01.020.
   Google Scholar
• Gea J. The future of biological therapies in COPD. Arch Bronconeumol. 2018;54(4):185–186. doi:10.1016/j.arbres.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934. doi:10.1164/rccm.200607-995OC.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023. doi:10.1056/NEJMoa1905248.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Chipps BE, Griffin NM, et al. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629–1633.e1622. doi:10.1016/j.jaci.2018.11.032.
   PubMed Web of Science ®Google Scholar
• Calle Rubio M, Rodriguez Hermosa JL, Soler-Cataluna JJ, et al. Medical care according to risk level and adaptation to Spanish COPD guidelines (Gesepoc): the epoconsul study. Arch Bronconeumol. 2018;54(5):270–279. doi:10.1016/j.arbres.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Miravitlles M, Esquinas C, et al. Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD groups and GesEPOC clinical phenotypes. Arch Bronconeumol. 2018;54(11):559–567. doi:10.1016/j.arbres.2018.03.021.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Navarrete BA, Soriano JB, et al. Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. COPD. 2018;13:2279–2288. doi:10.2147/COPD.S160842.
   Google Scholar
• Anzueto A, Calverley PMA, Mueller A, et al. Demographic characteristics and clinical outcomes in patients from Latin America versus the rest of the world: a TIOSPIR((R)) post-hoc analysis. Arch Bronconeumol. 2018;54(3):140–148. doi:10.1016/j.arbres.2017.11.010.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ. Clinical practice guidelines or personalized medicine in chronic obstructive pulmonary disease? Arch Bronconeumol. 2018;54(5):247–248. doi:10.1016/j.arbres.2017.08.002.
   PubMed Web of Science ®Google Scholar
• Alcazar Navarrete B, Ancochea Bermudez J, Garcia-Rio F, et al. Patients with chronic obstructive pulmonary disease exacerbations: recommendations for diagnosis, treatment and care. Arch Bronconeumol. 2019 Sep;55(9):478–487. doi:10.1016/j.arbres.2019.02.020.
   PubMed Web of Science ®Google Scholar
• Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52(5):1801261. doi:10.1183/13993003.01261-2018.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44. doi:10.1159/000330667.
   PubMed Web of Science ®Google Scholar
• Garcia Sanz MT, Gonzalez Barcala FJ. Establishing the prognosis of COPD exacerbations using risk scales from the point of view of the emergency department. Arch Bronconeumol. 2019 Jun 1. pii: S0300-2896(19)30246-7. doi:10.1016/j.arbres.2019.04.018.
   PubMedGoogle Scholar
• Shafuddin E, Chang CL, Hancox RJ. Comparing severity scores in exacerbations of chronic obstructive pulmonary disease. Clin Respir J. 2018;12(12):2668–2675. doi:10.1111/crj.12973.
   PubMed Web of Science ®Google Scholar